7.Heerspink HJL,Stefansson BV,Chertow GM,et al.Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease(DAPA-CKD)randomized controlled trial.Nephrology,dialysis,transplantation:official ...
近日,一项多国多中心、双盲、安慰剂对照的随机试验(DAPA-CKD 试验)评估了达格列净对 IgA 肾病患者的疗效、安全性,研究成果发表于Kidney Internatioal上(IF:18.998)。研究类型DAPA-CKD 是一项多国多中心、双盲、安慰剂对照的随机试验。纳排标准纳入标准:符合...
[3] Heerspink,H. J., et al. (2021). Effect of dapagliflozin on the rate of decline in kidneyfunction in patients with chronic kidney disease with and without type 2diabetes: a prespecified analysis from the DAPA-CKD trial. The Lancet Diabetes& Endocrinology. https://doi.org/10.1016/S2213...
Exploration of DAPA-CKD Trial End Points in a Broad Urine Albumin Creation Ratio Population DAPA-CKD研究终点的外推至更广泛的尿白蛋白肌酐比(UACR)人群 01研究背景 据估计,CKD全球患病率为8%-16%。CKD患者的发病和死亡风险增加。DAPA-CKD研究表明,SGLT2i达格列净可降低蛋白尿水平在200-5000mg/g的CKD患者...
Effects of Dapagliflozin in Patients without Diabetes and Microalbuminuria: An Exploratory Analysis From the DAPA-CKD Trial 达格列净对不合并糖尿病且存在微量白蛋白尿患者的影响:DAPA-CKD试验的探索性分析 01研究背景 DAPA-CKD研究表明,SGLT2i达格列净可减缓合并或不合并2型糖尿病的CKD患者的进行性肾功能减退。
DAPA-CKD 研究是首个评估 SGLT-2 抑制剂达格列净(Farxiga)联合标准治疗 CKD 患者(不论是否合并 2 型糖尿病)以肾脏终点为主要终点的,一项国际、多中心、随机、双盲、安慰剂对照、III 期临床研究,纳入伴或不伴 T2D 的 CKD2-4 期蛋白尿升高的 CKD 患者 4304 例(eGFR 25-75 ml/min/1.73m2,UACR 200-5000 ...
In the DAPA-CKD trial, treatment with the sodium-glucose cotransporter-2 (SGLT2) inhibitordapagliflozin(Farxiga,AstraZeneca) cut the incidence of substantially worsenedchronic kidney disease (CKD)by an average of 39% compared with placebo when added to standard treatment, with a number needed to ...
In the DAPA-CKD trial, treatment with the sodium-glucose cotransporter-2 (SGLT2) inhibitordapagliflozin(Farxiga,AstraZeneca) cut the incidence of substantially worsenedchronic kidney disease (CKD)by an average of 39% compared with placebo when added to standard treatment, with a number needed to ...
DAPA-CKD研究是首个针对伴或不伴2型糖尿病的CKD 2-4期患者的SGLT2i肾脏硬终点研究,该研究验证了SGLT2i达格列净在更广泛的CKD人群中的肾脏保护作用,无论是否合并2型糖尿病。今年DAPA-CKD多项研究入选,再证SGLT2i在不同CKD患者中的心脏、肾脏获益和安全性,为临床实践带来更多证据。
DAPA-CKD研究结果对进一步优化CKD患者治疗方案有重要意义,有望为CKD患者带来更加美好的未来。 参考文献: 1. 58th ERA-EDTA Congress 2021-Abstract Supplement-FC063-Dapagliflozin decreases albuminuria in patients with chronic kidney disease with and without type 2 diabetes: Insights from the DAPA-CKD trial ...